11/09/2022

Evolving Our Patient Access and Affordability Options

An Important Update from Janssen

Janssen is committed to helping patients receive the financial support they need. To help patients and providers better understand access and affordability options that will be available going forward, we have two important updates to share:

1. Effective January 1, 2023, Janssen donations to the Johnson & Johnson Patient Assistance Foundation (JJPAF), an independent, non-profit organization, will be reserved for uninsured patients who need assistance.*
   
   NOTE: You and your patients may have received communications previously from JJPAF with
   this information.
   
   
2. For patients with government, commercial, or employer group insurance who have inadequate coverage, Janssen is designing new access and affordability programs, which will be launched by January 1, 2023. The new Janssen programs will have similar eligibility and support offerings to the JJPAF for underinsured patients.

Patients should register at www.newprograminfo.com to receive more information on Janssen’s Patient Access and Affordability Programs best suited for their specific needs.

NOTE: JJPAF patients cannot be automatically enrolled in any new programs.

Important Next Steps for Providers
The new Janssen programs will have similar eligibility and support offerings to the JJPAF for underinsured patients. You can help us facilitate enrollment by encouraging your patients to register on the website: www.newprograminfo.com.

Patients may also call 1-833-742-0791 if they need assistance completing the form. Our team will be reaching out to registered patients no later than December 1, 2022, to understand their unique needs and match patients to an access and af fordability solution.

Please contact your Janssen Representative if you need additional support or have questions.

These new offerings will help patients get the support they need at the right time, from the right resource.

*The JJPAF will continue to support all IMBRUVICA® patients, including both insured and uninsured, that meet the JJPAF eligibility criteria for IMBRUVICA®.